analytical procedure validation; drug safety; impurity; LC-MS/MS; N-nitrosamines; pharmaceuticals; quality control
Abstract :
[en] Introduction
N-nitrosamines, a class of organic compounds recognized for their mutagenic and carcinogenic properties, have been raising major public health concerns following their detection in pharmaceuticals since 2018. These impurities can form during manufacturing processes, particularly through the interaction of amines with nitrosating agents. Regulatory bodies have launched procedures mandating a systematic investigation of medicinal products for N-nitrosamine contamination. This process involves risk evaluation, confirmatory testing, and the implementation of risk mitigation measures. Hyphenated analytical techniques, such as liquid chromatography-tandem mass spectrometry (LC-MS/MS), have become the standard for N-nitrosamine detection thanks to their high sensitivity and specificity.
Methods
In this work, based on a previously developed Quantitative Structure Retention Relationship approach for the determination of N-nitrosamines, sensitive LC-MS/MS methods were proposed and validated. These methods were subsequently applied to confirmatory testing of a marketed drug product.
Results
The methods were successfully validated in accordance with the ICH Q2 (R2) guidelines as limit tests for trace-level detection of N-nitrosamines. The confirmatory testing demonstrated the absence of most N-nitrosamines throughout the product’s shelf life, except for one potentially problematic impurity that nevertheless remained below the established acceptable limit, thus requiring routine quantitative analysis.
Discussion
These findings highlight the need for continued monitoring through routine analysis to ensure the safety and quality of pharmaceutical products.
Disciplines :
Pharmacy, pharmacology & toxicology
Author, co-author :
Zhang, Yue ; Université de Liège - ULiège > Unités de recherche interfacultaires > Centre Interdisciplinaire de Recherche sur le Médicament (CIRM)
Houari, Sabah ; Université de Liège - ULiège > Département de pharmacie > Chimie analytique
Van Laethem, Thomas; Laboratory of Pharmaceutical Analytical Chemistry, Department of Pharmacy, CIRM, University of Liege (ULiege)
Kumari, Priyanka; Laboratory of Pharmaceutical Analytical Chemistry, Department of Pharmacy, CIRM, University of Liege (ULiege)
Ziemons, Eric ; Université de Liège - ULiège > Département de pharmacie > Chimie analytique
Hubert, Philippe ; Université de Liège - ULiège > Département de pharmacie
Hubert, Cédric ; Université de Liège - ULiège > Département de pharmacie > Chimie analytique
Language :
English
Title :
A case study on N-nitrosamine investigation in a marketed drug: from analytical procedure validation to risk mitigation decision
Boetzel R. Schlingemann J. Hickert S. Korn C. Kocks G. Luck B. et al. (2023). A nitrite excipient database: a useful tool to support N-Nitrosamine risk assessments for drug products. J. Pharm. Sci. 112, 1615–1624. 10.1016/j.xphs.2022.04.01635500671
European Medicines Agency. EMA/369136/2020 assessment report, procedure under article 5(3) of regulation EC (no) 726/2004 nitrosamine impurities in human medicinal products (2020).
European Medicines Agency. (2025a). Questions and answers for marketing authorisation holders/applicants on the CHMP opinion for the article 5(3) of regulation (EC) no 726/2004 referral on nitrosamine impurities in human medicinal products, revision 23.
European Medicines Agency (2025b). Champix - supply shortage. Available online at: https://www.ema.europa.eu/en/medicines/human/shortages/champix (Accessed January 23, 2026).
European Parliament and the Council of the European Union (2002). Implementing council directive 96/23/EC concerning the performance of analytical methods and the interpretation of results. Official Journal European Communities.
Hansen S. W. McNally M. E. P. Usher K. M. (2013). Back to the basics: considering carryover, column back pressure, and wavelength when developing chromatographic methods. LCGC 31, 4.
Kruhlak N. L. Schmidt M. Froetschl R. Graber S. Haas B. Horne I. et al. (2024). Determining recommended acceptable intake limits for N-nitrosamine impurities in pharmaceuticals: development and application of the carcinogenic potency categorization approach (CPCA). Regul. Toxicol. Pharmacol. 150, 105640. 10.1016/j.yrtph.2024.10564038754805
Luo F. Liu Y. Xie Y. Hou W. Zhang L. Zhang Z. (2022). Simultaneous determination of 13 nitrosamine impurities in biological medicines using salting-out liquid-liquid extraction coupled with liquid chromatography tandem mass spectrometry. J. Pharm. Biomed. Anal. 218, 114867. 10.1016/j.jpba.2022.11486735679708
Moser J. Ashworth I. W. Harris L. Hillier M. C. Nanda K. K. Scrivens G. (2023). N-Nitrosamine formation in pharmaceutical solid drug products: experimental observations. J. Pharm. Sci. 112, 1255–1267. 10.1016/J.XPHS.2023.01.02736736774
Nudelman R. Kocks G. Mouton B. Ponting D. J. Schlingemann J. Simon S. et al. (2023). The nitrosamine “Saga”: lessons learned from five years of scrutiny. Org. Process Res. Dev. 27, 1719–1735. 10.1021/acs.oprd.3c00100
Panuwet P. Hunter Jr. R. E. D’Souza P. E. Chen X. Radford S. A. Cohen J. R. et al. (2016). Biological matrix effects in quantitative tandem mass spectrometry-based analytical methods: advancing biomonitoring. Crit. Rev. Anal. Chem. 46, 93–105. 10.1080/10408347.2014.98077525562585
Parr M. K. Joseph J. F. (2019). NDMA impurity in valsartan and other pharmaceutical products: analytical methods for the determination of N-nitrosamines. J. Pharm. Biomed. Anal. 164, 536–549. 10.1016/j.jpba.2018.11.01030458387
Schettino L. Benedé J. L. Chisvert A. (2023). Determination of nine prohibited N-nitrosamines in cosmetic products by vortex-assisted dispersive liquid-liquid microextraction prior to gas chromatography-mass spectrometry. RSC Adv. 13, 2963–2971. 10.1039/d2ra06553c36756441
Sgroi M. Vagliasindi F. G. A. Snyder S. A. Roccaro P. (2018). N-Nitrosodimethylamine (NDMA) and its precursors in water and wastewater: a review on formation and removal. Chemosphere 191, 685–703. 10.1016/j.chemosphere.2017.10.08929078192
Stokvis E. Rosing H. Beijnen J. H. (2005). Stable isotopically labeled internal standards in quantitative bioanalysis using liquid chromatography/mass spectrometry: necessity or not? Rapid Commun. Mass Spectrom. 19 (3), 401–407. 10.1002/rcm.179015645520
The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2024a). ICH Q14(R2) analytical procedure development.
The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2024b). ICH Q2(R2) validation of analytical procedures.
The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (2000). ICH Q6A specifications: test procedures and acceptance criteria for new drug substances and new drug products.
Thresher A. Foster R. Ponting D. J. Stalford S. A. Tennant R. E. Thomas R. (2020). Are all nitrosamines concerning? A review of mutagenicity and carcinogenicity data. Regul. Toxicol. Pharmacol. 116, 104749. 10.1016/j.yrtph.2020.10474932777431
U.S. Food and Drug Administration (2022). FDA updates and press announcements on nitrosamine in varenicline (chantix). Available online at: https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-and-press-announcements-nitrosamine-varenicline-chantix#:∼:text=Update%5B9%2F17%2F2021,N-nitroso-vareniclinelevels (Accessed January 23, 2026).
U.S. Food and Drug Administration. (2024). Control of nitrosamine impurities in human drugs guidance for industry. Revision 2.
U.S. Food and Drug Administration (2025). CDER nitrosamine impurity acceptable intake limits. Available online at: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cder-nitrosamine-impurity-acceptable-intake-limits (Accessed January 23, 2026).
Zhang Y. Widart J. Ziemons E. Hubert P. Hubert C. (2025a). N-nitrosamine risk assessment in pharmaceuticals: where are we from a regulatory point of view in 2025? J. Pharm. Biomed. Anal. Open 6, 100084. 10.1016/j.jpbao.2025.100084
Zhang Y. Houari S. Van Laethem T. Dispas A. Ziemons E. Hubert P. et al. (2025b). Innovative QSRR modeling approach for the development of an ultra-sensitive LC-MS/MS method for trace analysis of N-nitrosamines. J. Pharm. Biomed. Anal. Open 5, 100064. 10.1016/j.jpbao.2025.100064
Zhu J. Qu Y. Ye N. (2024). An automated carcinogenic potency categorization approach for nitrosamine drug substance-related impurities. Green Chem. 26, 3717–3721. 10.1039/D3GC03478J
